The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label, active drug controlled clinical trial that
aims to compare the effects of henagliflozin or metformin on myocardial tissue level
characteristics in type 2 diabetes patients with obesity. Eligible subjects with type 2
diabetes before randomisation and fulfilling all of the inclusion criteria and none of the
exclusion criteria will be randomised in a 1:1 ratio to henagliflozin 10 mg once a day or
metformin 1000 mg twice a day and treated for 24 weeks. The study includes five visits.